In this article we discuss the 5 Fastest Growing Biotech Companies in the US. If you want to read our detailed analysis of the biotech industry and why investors are flocking to biotech stocks, go to 15 Fastest Growing Biotech Companies in the US.
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind let’s take a look at the fastest growing biotech companies:
5. Novavax, Inc. (NASDAQ: NVAX)
Headquarters: Gaithersburg, Maryland
No. of employees: 522
Revenue (2018): $34.2 million
Revenue (2019): $18.6 million
Ranking 6th on our list of 15 fastest growing biotech companies in the US is Novavax, Inc., which produces vaccine candidates using the recombinant nanoparticle vaccine technology to respond to both known and emerging diseases. The company’s product pipeline with vaccine candidates in clinical development targets a range of infectious diseases such as pandemic influenza, seasonal influenza, respiratory syncytial virus (RSV), and Ebola virus (EBOV).
The firm’s vaccine candidates include ResVax which aims to protect infants from RSV disease through maternal immunization and NanoFlu which aims for treating seasonal influenza in older adults. Additionally, through Swedish subsidiary, Novavax is also developing immune-stimulating saponin-based adjuvants.
Further, the company is developing a COVID-19 vaccine that is in the preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.
According to the company’s recent update of the Phase 3 test results, its Covid-19 vaccine NVX-CoV2373 demonstrated 89.3% efficacy in the clinical trial conducted in the United Kingdom (UK).
4. CureVac N.V. (NASDAQ: CVAC)
Headquarters: Tuebingen, Germany.
No. of employees: 500
Revenue (2018): $12.9 million
Revenue (2019): $17.4 million
Founded in 2000, CureVac N.V. is a biopharmaceutical company that is engaged in developing messenger ribonucleic acid(mRNA) vaccines and drugs for treating cancer, infectious diseases and rare diseases.
The company’s pipeline primarily targets three domains: prophylactic vaccines, cancer immunotherapy, and protein-based therapy. Its major clinical programs entail ‘CV8102’ for treating four types of solid tumors, and ‘CV7202’ for potential vaccination against rabies.
The company initiated the Phase III trial of its Covid-19 vaccine ‘CVnCoV’ which is an optimized, non-chemically modified mRNA.
3. BioNTech SE (NASDAQ: BNTX)
Headquarters: Mainz, Germany
No. of employees: 1,800
Revenue (2018): $127.5 million
Revenue (2019): $108.6 million
Founded in 2008, BioNTech SE is a biotechnology company that engages in the discovery and development of patient-specific immunotherapies for the treatment of cancer, allergies, infectious diseases, and autoimmune disorders. It operates through two primary business units: Biotech Business and External Services.
Its extensive portfolio of candidate drugs includes individualized and off-the-shelf mRNA-based therapies, bi-specific antibodies, innovative chimeric antigen receptor T cells, targeted cancer antibodies, and small molecules immunomodulators. BioNTech has established a partnership with some leading pharmaceutical giants, including Pfizer, Eli Lilly, Roche, Genmab and Sanofi.
The U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for the BioNTech and Pfizer’s mRNA-based vaccine candidate ‘BNT162b2’ on December 11, 2020. In the phase 3 clinical trial the vaccine demonstrated 95% efficacy rate.
2. Seagen Inc. (NASDAQ: SGEN)
Headquarters: Bothell, Washington
No. of employees: 1,605
Revenue (2018): $654.7 million
Revenue (2019): $916 million
Founded in 1997 and previously recognized as Seattle Genetics, Inc., Seagen Inc. is a biotechnology company that focuses on conjugating drugs and antibodies to fight against cancer. Its flagship products include ADCETRIS for the treatment of Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV for the treatment of metastatic urothelial cancers and TUKYSA for treatment of certain metastatic HER2-positive breast cancers.
The company is also advancing a pipeline of new therapies for blood-related cancers and solid tumors. It has collaborations with Genentech, Millennium, Celldex Therapeutics, Inc., PSMA Development Company LLC and Genmab A/S.
1. Moderna, Inc. (NASDAQ: MRNA)
Headquarters: Cambridge, Massachusetts
No. of employees: 1,100
Revenue (2018): $135 million
Revenue (2019): $60 million
Topping our list of 15 fastest growing biotech companies in the US is Moderna, which is getting fame amid its successful COVID-19 vaccine. Founded in 2010, Moderna, Inc. is a biotechnology company that focuses on developing transformative drugs based on messenger ribonucleic acid (mRNA). Its drug development programs span cardiovascular diseases, immuno-oncology, infectious diseases, and rare diseases. It has an advanced pipeline of diverse programs among which 11 have joined clinical trials. Its clinical trials include mRNA-2416, mRNA-4157, mRNA-1893, and mRNA-1647 and among others.
Moderna’s COVID-19 vaccine, mRNA-1273, has shown an efficacy rate of 94.1% in the Pivotal Phase 3 Trial. On December 18, 2020, mRNA-1273 received emergency use authorization (EUA) from the U.S. FDA, making it the second authorized COVID-19 vaccine in the United States.
Baron Health Care Fund highlighted a few stocks in their Q4 2020 investor letter and Moderna Inc. (NASDAQ:MRNA) is one of them. Here is what Baron Health Care Fund said:
“Moderna, Inc. is a leader in the emerging field of mRNA-based vaccines and therapeutics. Shares pulled back from highs on likely profit taking, but we are looking past short-term fluctuations to focus on long-term potential. The pandemic has been a strong proof point of Moderna’s platform, with a COVID-19 vaccine coming to market in less than a year versus traditional vaccines that can take a decade. With this success under its belt, we think Moderna has potential to disrupt the entire biopharma space, from infectious disease vaccines to oncology and rare disease treatment.”
You can also take a peek at Top 10 Car Company Stocks to Invest In and Ray Dalio’s Top 10 Stock Picks for 2021.
